-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

636.O1.6 636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS

Symposia: Myelodysplastic Syndromes: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, MDS, Acquired Marrow Failure Syndromes, Adult, Translational Research, CHIP, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genomics, Bioinformatics, Chronic Myeloid Malignancies, Hematopoiesis, Diseases, Immunology, Computational biology, Myeloid Malignancies, Biological Processes, Emerging technologies, Molecular biology, Technology and Procedures, Gene editing, Study Population, Human, Pathogenesis
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Ballroom 20CD (San Diego Convention Center)
Moderators:
Mikko Myllymäki, MD, PhD, and Carmelo Gurnari, MD, PhD, ARRAY(0xeaad838)
Disclosures:
Myllymäki: Gilead: Research Funding.
4:00 PM

Won Jun Kim1*, Edie I. Crosse, PhD2*, Emma De Neef3*, Inaki Etxeberria1*, Erich Sabio1*, Eric Wang, PhD4*, Jan Philipp Bewersdorf, MD5, Sydney X. Lu6*, Andrea Belleville3*, Nina Fox1*, Cynthia Castro1*, Pu Zhang1*, Takeshi Fujino7*, Jennifer Lewis7*, Jahan Rahman8*, Beatrice Zhang7*, Jacob H. Winick1*, Alexander M. Lewis9*, Robert Stanley, MD, PhD1, Susan Dewolf, MD10*, Brigita Meskauskaite Urben11*, Meril Takizawa11*, Tobias Krause12*, Henrik Molina13*, Ronan Chaligne, PhD14*, Priya Koppikar15*, Jeffrey J. Molldrem, MD16*, Mathieu Gigoux17*, Taha Merghoub18*, Anthony F. Daniyan, MD19*, Benjamin D. Greenbaum, PhD20*, Christopher A. Klebanoff, MD1*, Robert K. Bradley, PhD21* and Omar Abdel-Wahab, MD22

1Memorial Sloan Kettering Cancer Center, New York
2Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
3Fred Hutchinson Cancer Research Center, Seattle
4The Jackson Laboratory For Genomic Medicine, Farmington, CT
5Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
6Stanford University, Palo Alto
7Memorial Sloan Kettering Cancer Center, New York, NY
8Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY
9Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
10Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
11Single-cell Analytics Innovation Lab, MSKCC, NEW YORK, NY
12Single-cell Analytics Innovation Lab, MSKCC, New York
13Rockefeller University, New York
14Single Cell Analytics and Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY
15MD Anderson Cancer Center, Houston
16Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
17McGill University, Montreal
18Weill Cornell Medical College, New York
19Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
20Computational Oncology, Memorial Sloan Kettering Cancer Center, New York
21Basic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
22Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

4:15 PM

Elizabeth Alice Bonner, BSc1,2, Axia Song, MD2*, Erica A Arriaga-Gomez, BSc2*, Katherine Gadek, PhD3*, Laura Baquero Galvis, BSc1,4*, Jonathan Linton, BA2*, Rasika A Venkataraman, MSc2,5,6, Sayantani Sinha, PhD2*, Anthony Rongvaux, PhD2,7*, Myron Evans II, PhD3*, Sergei Doulatov, PhD8 and Stanley C. Lee, PhD9,10

1Molecular and Cellular Biology Program, University of Washington School of Medicine, Seattle, WA
2Translational Science and Therapeutics Division, Fred Hutchison Cancer Center, Seattle, WA
3Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA
4Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA
5Molecular Medicine and Mechanism of Disease Program, University of Washington School of Medicine, Seattle, WA
6University of Washington, Department of Laboratory Medicine and Pathology, Seattle, WA
7Department of Immunology, University of Washington School of Medicine, Seattle, WA
8Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA
9Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
10Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA

4:30 PM

Qiaoli Li, MD1,2,3*, Fei Yang2,3,4*, Yuanyi Ling2,4*, Zhen Gao2,3,5*, Hong Pan2,3,6*, Weiwang Li2,3*, Jingyu Zhao, MSc2,3,5*, Liwei Fang2,3,5*, Yajing Chu2,7*, Weiping Yuan2,7 and Jun Shi, MD2,5*

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Tianjin, AL, China
2Tianjin Institutes of Health Science, Tianjin, China
3Red Blood Cell Diseases Center & Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Tianjin, China
5State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6Red Blood Cell Diseases Center & Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, AL, China
7State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

4:45 PM

Hidetaka Uryu, MD, PhD1*, Koichi Saeki2*, Hiroshi Haeno3*, Chiraag Kapadia, BA4, Ken Furudate, DMD, PhD5*, Jyoti Nangalia, MBBChir6, Michael Spencer Chapman, MBBS7*, Li Zhao8*, Joanne Hsu, MD, PhD9*, Chong Zhao10*, Shujuan Chen11*, Tomoyuki Tanaka12*, Zongrui Li12*, Hui Yang, PhD, MD13, Courtney D. DiNardo, MD, MSc14, Naval Daver, MD15, Naveen Pemmaraju, MD16, Nitin Jain, MD5, Farhad Ravandi, MBBS17, Jianhua Zhang, PhD18*, Xingzhi Song19*, Erika Thompson20*, Hongli Tang20*, Latasha Little19*, Curtis Gumbs21*, Robert Z. Orlowski, MD, PhD22,23, Muzaffar H. Qazilbash, MD24, Kapil N. Bhalla, MD5, Simona Colla, PhD5, Hagop M. Kantarjian, MD5, Rashmi Kanagal-Shamanna, MD25, Carlos E. Bueso-Ramos, MD, PhD26, Daisuke Nakada, PhD27, Jeffrey J. Molldrem, MD28, Gheath Alatrash, PhD, DO29, Andrew Futreal, PhD30*, Elizabeth J. Shpall, MD24, Margaret Goodell, PhD31,32, Guillermo Garcia-Manero, MD5 and Koichi Takahashi, MD, PhD5

1Leukemia, The UNIVERSITY of TEXAS, M.D. Anderson, Houston, TX
2Division of Integrated Research,, Tokyo University of Science, Research Institute for Biomedical Sciences, Noda, Japan
3Division of Integrated Research, Tokyo University of Science, Research Institute for Biomedical Sciences, Noda, Japan
4Departments of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Wellcome Sanger Institute, Hinxton, United Kingdom
7Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, United Kingdom
8Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston
10Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston
11Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
12Leukemia, MD Anderson Cancer Center, Houston, TX
13Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
14Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
15MD Anderson Cancer Center, Houston, TX
16Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
17Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
18Departments of Genomic Medicine, M. D. Anderson Cancer Center, Houston, TX
19Departments of Genomic Medicine, MD Anderson Cancer Center, Houston, TX
20Departments of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
21Departments of Genomic Medicine, MD Anderson, Houston, TX
22Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
23Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
24Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
25Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
26Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
27Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX
28Departments of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
29Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Pearland, TX
30Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
31Department of Molecular Cell Biology, Baylor College of Medicine, Houston, TX
32Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston

5:00 PM

Benjamin Kroger, BS1, Yuanyuan Ji, PhD1*, Toby Thomas, BS1*, Yazan F Madanat, MD1,2, Robert H. Collins, MD1,2, Valeria Visconte, PhD3, Carmelo Gurnari, MD, PhD4,5, Jaroslaw Maciejewski6 and Stephen Chung, MD1,2,7

1Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX
2Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH
4Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
5Cleveland Clinic Foundation, Cleveland, OH
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Children's Research Institute, University of Texas Southwestern, Dallas, TX

5:15 PM

Yongfang Xu1*, Huafeng Wang1,2*, Fang Chen3*, Jihyun Irizarry1*, Shawn Sharkas1*, Dandan Zhao1*, Mark Boldin4*, Guido Marcucci1 and Bin Zhang1

1Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, CA
2Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Monrovia, CA
4Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA

*signifies non-member of ASH